In late August, the South Florida Sun Sentinel published an op-ed lambasting the 340B program by Peter Pitts of the innocuous sounding Center for Medicine in the Public Interest. The commentary neglected to mention that "center" is heavily financed by drug companies and that Pitts himself has spent a good amount of his career as a PR executive for the drug industry. Pitts' … [Read more...]
AIDS Group Accuses Glaxo of $2.2 Million in 340B Overcharges
Files suit in California court to recover alleged overpayments from 2005 through 2013September 13, 2013 –AIDS Healthcare Foundation (AHF) has filed suit against drug manufacturer GlaxoSmithKline (GSK) claiming that the drug maker violated California law when it reportedly declined to credit AHF for alleged overpayments exceeding $2 million over nine years on 340B covered outpatient drugs. … [Read more...]
Apexus Launches New 340B FAQ Format
Technical assistance resource is now searchable by keywordSeptember 12, 2013—Apexus, the prime vendor for entities participating in the 340B program, has remodeled its website's frequently asked questions section. … [Read more...]
Rebates on Medicare Part B Drugs Deserve a Closer Look, OIG Says
Federal government could have recouped $3.1 billion that it spent during 2011September 12, 2013—The Department of Health and Human Services Office of Inspector General (OIG) has urged the Centers for Medicare and Medicaid Services (CMS) to consider calling for the enactment of a Medicare Part B drug rebate program. … [Read more...]
Onyx Pharmaceuticals Providing 340B Refunds on Kyprolis
Gives providers until end of this year to claim repayment for overchargesSeptember 9, 2013—Biopharmaceutical manufacturer Onyx, which is being purchased by biotech giant Amgen for $10.4 billion, has announced that 340B covered entities that bought its injectable oncology medication Kyprolis during the first quarter of 2013 might be eligible for refunds for overcharges. … [Read more...]
HRSA Releases Findings From 8 More 340B Provider Audits
42 down and 9 to go out of the 51 audits performed in 2012September 5, 2013—The Health Resources and Services Administration (HRSA) has released eight more brief summaries of findings from its audits of 340B covered entities in 2012, bringing the total to 42 out of 51 audits conducted last year. … [Read more...]
HRSA Publishes 340B Orphan Drug Exclusion List
Registry will govern sales covered by new regulation beginning Oct. 1September 4, 2013—The Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) has published its first quarterly list of orphan drugs subject to exclusion from 340B pricing in certain circumstances. … [Read more...]